Duopharma Biotech Berhad Statistics

Total Valuation

Duopharma Biotech Berhad has a market cap or net worth of MYR 1.20 billion. The enterprise value is 1.47 billion.

Market Cap	1.20B
Enterprise Value	1.47B

Important Dates

The next estimated earnings date is Thursday, February 20, 2025.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	Aug 29, 2024

Share Statistics

Duopharma Biotech Berhad has 961.94 million shares outstanding. The number of shares has increased by 0.60% in one year.

Current Share Class	n/a
Shares Outstanding	961.94M
Shares Change (YoY)	+0.60%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.31%
Owned by Institutions (%)	72.16%
Float	943.87M

Valuation Ratios

The trailing PE ratio is 21.46 and the forward PE ratio is 15.57. Duopharma Biotech Berhad's PEG ratio is 0.76.

PE Ratio	21.46
Forward PE	15.57
PS Ratio	1.53
PB Ratio	1.73
P/TBV Ratio	1.82
P/FCF Ratio	17.14
P/OCF Ratio	n/a
PEG Ratio	0.76

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.04, with an EV/FCF ratio of 20.95.

EV / Earnings	26.21
EV / Sales	1.87
EV / EBITDA	11.04
EV / EBIT	16.36
EV / FCF	20.95

Financial Position

The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.76.

Current Ratio	4.33
Quick Ratio	3.02
Debt / Equity	0.76
Debt / EBITDA	3.96
Debt / FCF	7.52
Interest Coverage	3.50

Financial Efficiency

Return on equity (ROE) is 8.18% and return on invested capital (ROIC) is 4.51%.

Return on Equity (ROE)	8.18%
Return on Assets (ROA)	4.10%
Return on Capital (ROIC)	4.51%
Revenue Per Employee	477,288
Profits Per Employee	33,978
Employee Count	1,650
Asset Turnover	0.58
Inventory Turnover	2.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -1.57% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-1.57%
50-Day Moving Average	1.28
200-Day Moving Average	1.24
Relative Strength Index (RSI)	47.03
Average Volume (20 Days)	371,465

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Duopharma Biotech Berhad had revenue of MYR 787.53 million and earned 56.06 million in profits. Earnings per share was 0.06.

Revenue	787.53M
Gross Profit	281.44M
Operating Income	89.83M
Pretax Income	69.62M
Net Income	56.06M
EBITDA	129.71M
EBIT	89.83M
Earnings Per Share (EPS)	0.06

Full Income Statement

Balance Sheet

The company has 260.42 million in cash and 527.41 million in debt, giving a net cash position of -266.99 million or -0.28 per share.

Cash & Cash Equivalents	260.42M
Total Debt	527.41M
Net Cash	-266.99M
Net Cash Per Share	-0.28
Equity (Book Value)	696.05M
Book Value Per Share	0.72
Working Capital	557.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 93.62 million and capital expenditures -23.48 million, giving a free cash flow of 70.15 million.

Operating Cash Flow	93.62M
Capital Expenditures	-23.48M
Free Cash Flow	70.15M
FCF Per Share	0.07

Full Cash Flow Statement

Margins

Gross margin is 35.74%, with operating and profit margins of 11.41% and 7.12%.

Gross Margin	35.74%
Operating Margin	11.41%
Pretax Margin	8.84%
Profit Margin	7.12%
EBITDA Margin	16.47%
EBIT Margin	11.41%
FCF Margin	8.91%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.24%.

Dividend Per Share	0.03
Dividend Yield	2.24%
Dividend Growth (YoY)	21.74%
Years of Dividend Growth	n/a
Payout Ratio	48.04%
Buyback Yield	-0.60%
Shareholder Yield	1.64%
Earnings Yield	4.66%
FCF Yield	5.83%

Dividend Details

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date	Sep 6, 2021
Split Type	Forward
Split Ratio	1.3333333333

Scores

Duopharma Biotech Berhad has an Altman Z-Score of 2.72. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.72
Piotroski F-Score	n/a